Study points to the futility of urine tests for salbutamol doping

Salbutamol, also known as albuterol, is a medication that opens upconstrictedmedium and large airways in the lungs and is often used to treat asthma. Because high doses are suspected by some to also have an anabolic effect, its daily dosage is restricted by the World Anti-Doping Agency, which uses urine tests to determine violations. A new British Journal of Clinical Pharmacology study shows thatlarge variability in urine concentrations, however, lead toinfeasibility of determining an administered dose from a single untimed urine sample.

The authors noted that the current threshold inadvertently leads to incorrect assumptions of violation, whereas many violations will go unnoticed, especially when samples are taken long after drug administration. These issues, combined with the dubious assertion of its anabolic effect, indicate that the large effort involved in testing should be reconsidered.

"Using available pharmacological knowledge, we demonstrate that the current approach to detect excessive salbutamol use is fundamentally flawed and cannot differentiate between illegal and allowed use," said co-authorJules Heuberger, of the Centre for Human Drug Research, in Leiden, The Netherlands. "If the doping community is determined to control for excessive salbutamol use, these procedures should be changed, ideally in collaboration with clinical pharmacologists."

More information: Jules A.A.C. Heuberger et al. Futility of current urine salbutamol doping control, British Journal of Clinical Pharmacology (2018). DOI: 10.1111/bcp.13619

Provided by Wiley
Citation: Study points to the futility of urine tests for salbutamol doping (2018, May 3) retrieved 9 February 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Novel solid forms of the anti-inflammatory drug oxaprozin may lead to a new combined asthma therapy


Feedback to editors